Sanofi's $2.2B Acquisition of Inhibrx Strengthens Drug Pipeline
TL;DR Summary
Sanofi is acquiring California-based biotech company Inhibrx for up to $2.2 billion to bolster its pipeline of inflammation-targeting drugs, with a focus on Inhibrx’s experimental therapy for AATD, a disease affecting the lungs and liver. Inhibrx's other drug candidates, including cancer-targeting immunotherapies, will be part of a new company led by Inhibrx's founder and CEO.
Topics:business#acquisition#biotech#business-healthcare#inflammation-targeting-drugs#pipeline-expansion#sanofi
- Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal STAT
- Sanofi inks $1.7B Inhibrx buyout, snagging rare disease drug but spinning out cancer programs FierceBiotech
- Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion The Wall Street Journal
- Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B PR Newswire
- Sanofi Buys Inhibrx for Up to $2.2B to Bolster Inflammation Drug Pipeline BioSpace
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
0 min
vs 1 min read
Condensed
58%
131 → 55 words
Want the full story? Read the original article
Read on STAT